Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor, Exanta Promotions Will Focus On Dosing Advantages

Executive Summary

One of AstraZeneca's promotional messages for its statin Crestor (rosuvastatin) will likely focus on the ability of the 10 mg dose to achieve target cholesterol levels without the need for up-titration

You may also be interested in...



AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says

AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials

AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says

AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials

AstraZeneca Crestor 10 mg Fixed Starting Dose Supported By Committee

Dosing for AstraZeneca's statin Crestor in the general population should start with a fixed dose of 10 mg, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended July 9

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel